

Accepted Manuscript

TRPV1 Antagonist with High Analgesic Efficacy: 2-Thio Pyridine C-region Analogues of 2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides

Tae-Hwan Ha, HyungChul Ryu, Sung-Eun Kim, Ho Shin Kim, Jihyae Ann, Phuong-Thao Tran, Van-Hai Hoang, Karam Son, Minghua Cui, Sun Choi, Peter M. Blumberg, Robert Frank, Gregor Bahrenberg, Klaus Schiene, Thomas Christoph, Sven Frommann, Jeewoo Lee


PII: S0968-0896(13)00697-4
DOI: <http://dx.doi.org/10.1016/j.bmc.2013.08.015>
Reference: BMC 11031

To appear in: *Bioorganic & Medicinal Chemistry*

Received Date: 22 July 2013
Revised Date: 5 August 2013
Accepted Date: 5 August 2013

Please cite this article as: Ha, T-H., Ryu, H., Kim, S-E., Kim, H.S., Ann, J., Tran, P-T., Hoang, V-H., Son, K., Cui, M., Choi, S., Blumberg, P.M., Frank, R., Bahrenberg, G., Schiene, K., Christoph, T., Frommann, S., Lee, J., TRPV1 Antagonist with High Analgesic Efficacy: 2-Thio Pyridine C-region Analogues of 2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides, *Bioorganic & Medicinal Chemistry* (2013), doi: <http://dx.doi.org/10.1016/j.bmc.2013.08.015>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TRPV1 Antagonist with High Analgesic Efficacy: 2-Thio Pyridine C-region Analogues of 2-(3-Fluoro-4- methylsulfonylaminophenyl)propanamides

Tae-Hwan Ha,^a HyungChul Ryu,^a Sung-Eun Kim,^a Ho Shin Kim,^a Jihyae Ann,^a Phuong-Thao Tran,^a Van-Hai Hoang,^a Karam Son,^b Minghua Cui,^b Sun Choi,^b Peter M. Blumberg,^c Robert Frank,^d Gregor Bahrenberg,^d Klaus Schiene,^d Thomas Christoph,^d Sven Frommann,^d Jeewoo Lee^{*,a}

^a Laboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Korea

^b National Leading Research Lab (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy, Division of Life and Pharmaceutical Sciences, and Global Top5 Research Program, Ewha Womans University, Seoul 120-750, Korea

^c Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

^d Grunenthal Innovation, Grunenthal GmbH, D-52078 Aachen, Germany

** To whom correspondence should be addressed.*

Phone: 82-2-880-7846

Fax: 82-2-888-0649

E-mail: jeewoo@snu.ac.kr

Key Words: TRPV1 antagonists, analgesic, capsaicin, resiniferatoxin

Abstract

A series of 2-thio pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides were investigated as *h*TRPV1 antagonists. Among them, compound **24S** showed stereospecific and excellent TRPV1 antagonism of capsaicin-induced activation. Further, it demonstrated strong anti-allodynic in a rat neuropathic pain model. Consistent with its action *in vitro* being through TRPV1, compound **24S** blocked capsaicin-induced hypothermia in mice. Docking analysis of **24S** with our *h*TRPV1 homology model was performed to identify its binding mode.

1. Introduction

The transient receptor potential V1 (TRPV1) receptor is a molecular integrator of nociceptive stimuli predominantly expressed on sensory neurons.¹ It is activated by multiple endogenous agonists including protons,² noxious heat,³ and inflammatory lipid mediators^{4,5} as well as by natural products such as capsaicin (CAP)⁶ and resiniferatoxin (RTX)⁷.

The pharmacological blockade of TRPV1, by inhibiting the transmission of nociceptive signaling from the periphery to the CNS, provides a promising strategy for the development of novel analgesics.⁸ Since the molecular cloning of TRPV1 in 1997,³ a massive effort to identify potent and selective TRPV1 antagonists has been made to develop clinical candidates as novel analgesic and antiinflammatory agents, particularly for neuropathic pain. The clinical development and therapeutic potential of TRPV1 antagonists have been extensively reviewed.⁹⁻¹⁵




Figure 1. Lead TRPV1 antagonists

Recently, we reported that compound **2** showed highly selective and potent antagonism of TRPV1 with $K_{i(\text{CAP})} = 0.2 \text{ nM}$ and $\text{IC}_{50(\text{pH})} = 6.3 \text{ nM}$, being thus approximately 100-fold and 20-fold better than prototype **1**¹⁶ for CAP and pH antagonism, respectively (**Figure 1**).¹⁷ In addition, compound **2** demonstrated strong anti-allodynic activity in a neuropathic pain model with almost no off target effects and blocked capsaicin-induced hypothermia in mice. The structural analysis indicated that the enhanced potency of **2** was attributed to the additional 4-methylpiperidine moiety in **2** compared to **1**, which provided a new hydrophobic interaction with

the receptor. Indeed, the docking analysis using our hTRPV1 homology model indicated that the 4-methylpiperidinyl group in the C-region of **2** made additional hydrophobic interactions with the hydrophobic region composed of Met514 and Leu515, an interaction not occurring with **1**.¹⁸





Figure 2. General structure of the designed compounds

In order to further optimize the 2-substituent in the *N*-(6-trifluoromethyl-pyridin-3-ylmethyl) C-region, we have investigated the structure activity relationship of 2-thio derivatives (**Figure 2**) as hTRPV1 antagonists. With a selected potent antagonist in the series, we further characterized target engagement by assessing its potential to inhibit capsaicin-induced hypothermia and its anti-allodynic activity in animal models and performed molecular modeling with our hTRPV1 homology model.

2. Result and discussion

2.1. Chemistry

The key intermediate of the C-region **3** was prepared as described in the previous report.¹⁷ A library of thiols were reacted with **3** to afford 2-thio substituted pyridines **4** and then their nitrile groups were reduced to yield the corresponding primary amines **5**. The amines were coupled with racemic or chiral 2-(3-fluoro-4-methylsulfonylaminophenyl) propanamide **6** to provide the final compounds **7-39**, respectively.



Scheme 1. Syntheses of 2-thio pyridine C-region analogues

Reagents and conditions: (a) [Method A] RSH, DBU, CH₃CN, rt; [Method B] RSH, NaH, DMF, rt (b) 2M BH₃-SMe₂ in THF (c) **6**, EDC, HOBt, DMF


2.2. Structure-Activity Relationship (SAR) Analysis.







The synthesized TRPV1 ligands were evaluated *in vitro* for antagonism as measured by inhibition of activation by capsaicin (CAP) and pH as indicated. The assays were conducted using a fluorometric imaging plate reader (FLIPR) with human TRPV1 heterologously expressed in Chinese hamster ovary (CHO) cells.¹⁷ The results are summarized in Tables 1-3, together with the potencies of the previously reported antagonists **1** and **2**.^{16,17}

To investigate the SAR for 2-thio derivatives of the pyridine C-region, we began with the 2-alkylthio derivatives (Table 1). Previous SAR analysis with a series of 2-alkoxy derivatives indicated that the 2-butyloxy group was among the most optimal with low lipophilicity and potent antagonism.¹⁸ The 2-butythio derivative **7** likewise proved to be a potent antagonist with $K_{i(\text{CAP})} = 0.7$ nM and $\text{IC}_{50(\text{pH})} = 40.4$ nM but was nonetheless ca. 2-fold and 5-fold less potent than the racemate of **2** ($K_{i(\text{CAP})} = 0.3$ nM and $\text{IC}_{50(\text{pH})} = 8.4$ nM), respectively. As the number of carbons in the chain further increased, antagonistic activity decreased as seen with **8** and **9**. The branched derivative **10** showed better antagonism than the corresponding straight derivative **8** by 3-fold. With potent antagonist **7**, we explored the SAR at its terminal position by introducing different types of group

s. The lipophilic moieties such as trifluoromethyl (**11**), bromo (**12**) and phenoxy (**13**) caused a reduction in activity compared to **7** but still provided good antagonism. The polar moieties such as hydroxyl (**14**) and dimethylamine (**15**) led to a further reduction in activity. However, the introduction of cyclic amines such as pyrrolidine (**16**), piperidine (**17**) and 4-methylpiperidine (**18**) produced reasonable antagonism in the range of $K_{i(\text{CAP})} = 2\text{--}3$ nM. The morpholine derivative (**19**) showed weak antagonism due to its polar oxygen, as was the case with **14**. The carboxylate moieties (**20–22**) similarly reduced the potency because of their polarity. The SAR analysis in this series of 2-alkylthio groups indicated that the number of 4 carbons (**7**) appeared to be optimal for antagonism, as had been observed for the 2-alkoxy groups, and the incorporation of any moiety at the terminus of the 2-alkylthio group led to a reduction in potency.

Table 1. *In vitro* hTRPV1 Antagonistic Activities for 2-Alkylthio Derivatives



| | R | K_i [CAP] (nM) | IC_{50} [pH] (nM) | | R | K_i [CAP] (nM) | IC_{50} [pH] (nM) |
|----------|---|---------------------|------------------------|-----------|--|---------------------|------------------------|
| 1 | | 28 | 1281 | 14 |  | WE | WE |
| 2 | | 0.2 | 6.3 | 15 |  | 27.4 | 1498 |
| 7 |  | 0.7 | 40.4 | 16 |  | 3.3 | 312 |
| 8 |  | 2.5 | 95.6 | 17 |  | 3.0 | 250 |

| | | | | | | | |
|-----------|--|-----|-----|-----------|--|------|------|
| 9 | | 5.6 | 719 | 18 | | 2.9 | 217 |
| 10 | | 0.7 | 82 | 19 | | WE | NE |
| 11 | | 4.3 | WE | 20 | | WE | WE |
| 12 | | 7 | 68 | 21 | | 48.2 | 1099 |
| 13 | | 2.3 | 118 | 22 | | 85 | WE |

Next, the SAR of 2-cycloalkylthio derivatives was investigated (**Table 2**). 2-Cyclopentylthio (**23**) and 2-cyclohexylthio (**24**) analogues exhibited potent antagonism with $K_{i(CAP)} = 1.2$ and 0.9 nM, respectively, which were 2- and 4-fold better than the corresponding acyclic 2-alkylthio derivatives **8** and **9**. The result was contrary to that of the 2-alkoxy and 2-cycloalkoxy derivatives and the comparison will be discussed in detail in Table 4. The two stereoisomers of **24** showed stereospecific antagonism, as previously reported,¹⁹ in which eutomer **24S** proved to have excellent antagonism with $K_{i(CAP)} = 0.4$ nM.

To examine the effect of substituents on potent antagonist **24**, its derivatives were further investigated. The sulfur oxidation of **24**, providing sulfoxide **25** and sulfone **26**, led to a dramatic loss of activity. Whereas the 4-methyl group in **27** enhanced antagonistic potency by 2-fold, the 2-methyl group in **28** reduced potency by 2-fold compared to **24**, respectively. The 4-ethyl derivative **29** showed similar activity to that of the parent **24**, while the 4-*t*-butyl group caused a slight decrease of activity. The 2-cyclohexylmethylthio derivative **31**, the one carbon elongated product of **24**, was 2.5-fold less potent than **24**. The SAR analysis in this series of 2-cycloalkylthio groups indicated that the 2-cyclohexylthio

o derivative **24** appeared to be optimal for antagonism and the 4-methyl and 4-ethyl groups on the ring were tolerable for potency.

Table 2. *In vitro* hTRPV1 Antagonistic Activities for 2-Cycloalkylthio Derivatives

| | R | K _i [CAP] (nM) | IC ₅₀ [pH] (nM) | | R | K _i [CAP] (nM) | IC ₅₀ [pH] (nM) |
|------------|---|------------------------------|-------------------------------|-----------|---|------------------------------|-------------------------------|
| 23 | | 1.2 | WE | 27 | | 0.5 | 180 |
| 24 | | 0.9 | WE | 28 | | 1.9 | NE |
| 24S | | 0.4 | WE | 29 | | 1.0 | WE |
| 24R | | 43.5 | WE | 30 | | 2.6 | 89.6 |
| 25 | | WE | NE | 31 | | 2.3 | 254 |
| 26 | | WE | NE | | | | |

Next, we sought to evaluate the SAR of 2-benzylthio and 2-arylmethylthio derivatives since previous SAR analysis in a series of 2-alkyloxy derivatives indicated that a 2-benzyloxy derivative showed potent antagonism (**Table 3**).¹⁸ Substituted 2-benzylthio derivatives (**32-36**) exhibited similar and reasonable antagonism with a range of K_i(CAP) = 2.3-8.7 nM but were less potent than the corresponding 2-benzyloxy surrogates. 2-Arylmethylthio derivatives (**37, 38**) showed further reduced activities. The 2-phenylethylthio derivative (**39**) displayed good antagonism.

Table 3. *In vitro* hTRPV1 Antagonistic Activities for 2-Arylmethylthio Derivatives

| | R | K _i [CAP] (nM) | IC ₅₀ [pH] (nM) | | R | K _i [CAP] (nM) | IC ₅₀ [pH] (nM) |
|----|---|------------------------------|-------------------------------|----|---|------------------------------|-------------------------------|
| 32 | | 8.7 | 674 | 36 | | 3.9 | 71 |
| 33 | | 3.2 | 764 | 37 | | 14.6 | WE |
| 34 | | 2.3 | 279 | 38 | | 15 | WE |
| 35 | | 4.9 | 620 | 39 | | 1.9 | 111 |

Detailed *in vitro* activity of **24S**, the most promising antagonist in this study, was investigated for multiple TRPV1 activators including capsaicin, *N*-arachidonoyl dopamine (NADA), pH and heat (45°C), and compared to the activity of lead **2** (Table 4). Compound **24S** showed excellent antagonism of capsaicin and NADA comparable to **2**, but showed poor antagonism toward pH and heat, in contrast to **2**. The differential activity of **24S** compared to **2** is consistent with the different *in vivo* responses described below.

Table 4. *In Vitro* hTRPV1 Antagonistic Activities for **2** and **24S** to Multiple Activators

| Activators, parameter | 2 | 24S |
|----------------------------------|----------|------------|
| CAP (f)K _i (nM) | 0.2 | 0.4 |
| NADA (f)K _i (nM) | 0.01 | 0.05 |
| pH, IC ₅₀ (nM) | 6.3 | >1,000 |
| heat 45°C, IC ₅₀ (nM) | 0.8 | 22.3 |

2.3. *In vivo* Activity

The analgesic activity of compound **24S** was evaluated orally in the rat Bennett model²⁰ as a neuropathic pain model and its activity was compared to those of reference

compounds **1**, **2** and pregabalin (**Figure 3**). Previously, we reported that antagonist **2** showed excellent anti-allodynic efficacy in that model with $ED_{50} = 0.9$ mg/Kg po (max 60 % at 3.16 mg/Kg) and was better than **1** ($ED_{50} = 26.6$ mg/Kg, max 59% at 46.4 mg/Kg) and pregabalin ($ED_{50} = 42.2$ mg/Kg, max 69% at 100 mg/Kg).¹⁷ We now find that the analgesic potency of **24S** showed dose-dependent efficacy with $ED_{50} = 0.19$ mg/Kg po (max 75% at 10 mg/Kg) and was superior to **2**.





Figure 3. Comparison of analgesic activities of compound **24S** and reference compounds on CCI-induced cold allodynia after oral administration in rats. Data, n=10, mean \pm SEM, * $p < 0.05$ vs vehicle. MPE, maximal possible effect.

Consistent with its *in vitro* mechanism of action, *in vivo* **24S** also blocked response to capsaicin (**Figure 4**). The intraperitoneal injection of 3 mg/kg capsaicin resulted in a decrease of body temperature as expected,^{21,22} with a reduction from 37.6 ± 0.1 to 34.0 ± 0.1 °C ($p < 0.05$) at 15 min post capsaicin injection and to 35.8 ± 0.4 °C ($p < 0.05$) at 30 min post capsaicin injection. By 60 min body temperature had returned to normal (37.1 ± 0.1 to 37.0 ± 0.1 °C; $p = 1.00$). The oral administration of 0.3 mg/kg **24S** (15 min before capsaicin injection) completely inhibited the effect of capsaicin on body temperature at 30 min, with partial inhibition of the effect at 15 min.

(A)



(B)




Figure 4. Effect of **24S** on capsaicin-induced hypothermia in mice. Data, n=5, mean \pm SEM, * $p < 0.05$ vs vehicle. MPE, maximal possible effect of compound.

2.4. Molecular Modeling

In order to investigate the binding interactions of **24S**, a flexible docking study was performed using our human TRPV1 (hTRPV1) model¹⁷ built based on our rat TRPV1 (rTRPV1) model²³. The docking result demonstrated that **24S** binds very well at the capsaicin binding site, as we had previously described for **2**.¹⁷ The 4-(methylsulfonylamino)phenyl group (A-region)

occupied the deep bottom hole and was involved in hydrophobic interactions with Tyr511 and Ile564 (**Figure 5**). The fluorine atom of the A-region participated in hydrogen bonding with Lys571. The amide group (B-region) made a hydrogen bond with Tyr511 and also contributed to the appropriate positioning of the C-region for hydrophobic interactions.

In the C-region, the cyclohexylthio group initially was expected to orient toward the hydrophobic region composed of Met514 and Leu515 as did the 4-methylpiperidinyl group of **2**.¹⁷ However, the modeling indicated that the cyclohexyl ring was extended toward the upper hydrophobic pocket composed of Leu547 and Thr550 to generate the hydrophobic interaction, and the sulfur atom made the hydrophobic interaction with Leu515. It seems that the bent conformation of the thioether linker allowed the cyclohexylthio group to make hydrophobic interactions with both hydrophobic regions. In addition, the pyridine ring nitrogen in the C-region made a hydrogen bond with Tyr511.




Figure 5. Flexible docking result of **24S** in the hTRPV1 model.

(A) Binding mode of **24S**. The key interacting residues are marked and displayed as capped-stick with carbon atoms in white. The helices are colored in gray and the helices of the adjacent monomer are depicted in line ribbon. **24S** is displayed as ball-and-stick with carbon atoms in magenta. The van der Waals surface of the ligand is presented with its lipophilic potential property. Hydrogen bonds are shown as black dashed lines and non-polar hydrogens are undisplayed for clarity. (B) Surface representations of the docked ligand and hTRPV1. The Fast

Connolly surface of hTRPV1 was generated by MOLCAD and colored by the lipophilic potential property. The surface of hTRPV1 is Z-clipped and that of the ligand is in its carbon color for clarity. (C) Van der Waals surface of the ligand colored by its lipophilic potential property.

3. Conclusion

The structure activity relationships of 2-thio pyridine C-region derivatives of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as hTRPV1 antagonists were investigated. The analysis indicated that 2-cycloalkylthio derivatives showed better antagonism than the corresponding 2-alkylthio ones, in contrast to the findings for a series of 2-alkyloxy derivatives. Among the 2-thio pyridine derivatives, compound **24S** showed stereospecific and excellent TRPV1 antagonism with $K_{i(CAP)} = 0.4$ nM. It demonstrated dose-dependent and strong anti-allodynic activity with $ED_{50} = 0.19$ mg/Kg po (max 75% at 10 mg/Kg) in a neuropathic pain model in the rat and was superior to previous lead **2**. Consistent with its action *in vitro* being through TRPV1, compound **24S** blocked capsaicin-induced hyperthermia. Docking analysis of **24S** with our hTRPV1 homology model indicated that the 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamide (A and B-regions) made critical hydrophobic and hydrogen bonding interactions with Tyr511, and the cyclohexyl group and the sulfur atom in the C-region made two hydrophobic interactions with the pocket composed of Leu547/Thr550 and Leu515, respectively.

4. Experimental

4.1. Chemistry

4.1.1. General

All chemical reagents were commercially available. Melting points were determined on a Büchi Melting Point B-540 apparatus and are uncorrected. Silica gel column chromatography was performed on silica gel 60, 230-400 mesh, Merck. Nuclear magnetic resonance spectra were

recorded on a JEOL JNM-LA 300 and Bruker Avance 400 MHz FT-NMR spectrometer. Chemical shifts are reported in ppm units with Me₄Si as a reference standard. Mass spectra were recorded on a VG Trio-2 GC-MS and 6460 Triple Quad LC/MS. All final compounds were purified to >95% purity, as determined by high-performance liquid chromatography (HPLC). HPLC was performed on an Agilent 1120 Compact LC (G4288A) instrument using a Agilent Eclipse Plus C18 column (4.6 x 250 mm, 5 μ m) and Daicel Chiralcel OD-H column (4.6 x 250 mm, 5 μ m). Optical rotations were measured in a JASCO DIP-2000 digital polarimeter.

4.1.2. General Procedure for the Synthesis of **4**

4.1.2.1. Method A

A mixture of compound **3** (2 mmol), thiol (4 mmol) and DBU (4 mmol) were dissolved in acetonitrile (15 mL) and stirred for 12 h at room temperature. The reaction mixture was diluted with water and extracted with EtOAc several times. The combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc: hexanes =1:15 as eluant.

4.1.2.2. Method B

A solution of thiol (2.4 mmol) in DMF (5 mL) was treated with sodium hydride (2.6 mmol). The resulting suspension was cooled to 0 °C and compound **3** (2 mmol) was added. After stirring overnight at room temperature, the reaction mixture was diluted with water and extracted with EtOAc several times. The combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc: hexanes =1:15 as eluant.

4.1.3. General Procedure for the Synthesis of **5**

To a stirred solution of nitrile (2 mmol) in anhydrous THF (10 mL) was added $\text{BH}_3\text{-SMe}_2$ (2.0 M in THF, 3 mL, 6 mmol) at room temperature. After being refluxed for 8 hrs, the mixture was cooled to room temperature, 2 N HCl was added, and the solution then refluxed for 30 min. After cooling to room temperature, the mixture was neutralized with 2 N NaOH and extracted with EtOAc several times. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using $\text{CH}_2\text{Cl}_2\text{:MeOH}=10\text{:}1$ as eluant.

4.1.4. General Procedure for the Syntheses of 7-39

A mixture of amine **5** (1.2 mmol), acid **6** (1.0 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2 mmol) in DMF (5 mL) was stirred for 12 h at room temperature. The reaction mixture was diluted with water and extracted with EtOAc several times. The aqueous phase was saturated with NaCl and extracted with EtOAc again. The combined organic extracts were washed with 1N HCl and brine, dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes=1:2 as eluant.

4.1.4.1. 2-(3-Fluoro-4-methanesulfonylamino-phenyl)-(N-(2-(butylthio)-6-(trifluoromethyl)pyridin-3-ylmethyl)propionamide (7)

71% yield, white solid, mp = 105-107 °C, ^1H NMR (300 MHz, CDCl_3) δ 7.50-7.42 (m, 2 H), 7.27 (s, 1 H), 7.13 (dd, 1 H, J = 8.1 Hz), 7.07 (d, 1 H, J = 8.1 Hz), 6.98 (bs 1 H), 6.33 (bt, 1 H), 4.36 (m, 2 H), 3.56 (q, 1 H, J = 6.9 Hz), 3.22 (t, 2 H, J = 7.5 Hz), 3.01 (s, 3 H), 1.66 (m, 2 H), 1.50-1.38 (m, 5 H), 0.93 (t, 3 H, J = 7.2 Hz); MS (FAB) m/z 508 (M+H).

4.1.4.2. 2-(3-Fluoro-4-(methylsulfonylamido)phenyl)-N-((2-(pentylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (8)

65% yield, white solid, mp = 126-129 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.52-7.42 (m, 2 H), 7.27 (s, 1 H), 7.13 (dd, 1 H, *J* = 8.0 Hz), 7.07 (d, 1 H, *J* = 8.2 Hz), 6.98 (bs 1 H), 6.33 (bt, 1 H), 4.36 (m, 2 H), 3.58 (q, 1 H, *J* = 6.9 Hz), 3.25 (t, 2 H, *J* = 7.5 Hz), 3.05 (s, 3 H), 1.66 (m, 2 H), 1.58-1.48 (m, 5 H), 1.23-1.09 (m, 2 H), 0.90 (t, 3 H, *J* = 7.1 Hz); MS (FAB) *m/z* 522 (M+H).

4.1.4.3. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-*N*-((2-(hexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (9)

72% yield, white solid, mp = 102-105 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.51-7.40 (m, 2 H), 7.24 (s, 1 H), 7.11 (dd, 1 H, *J* = 8.1 Hz), 7.05 (d, 1 H, *J* = 8.0 Hz), 6.94 (bs 1 H), 6.31 (bt, 1 H), 4.31 (m, 2 H), 3.58 (q, 1 H, *J* = 6.7 Hz), 3.24 (t, 2 H, *J* = 7.3 Hz), 3.03 (s, 3 H), 1.66 (m, 2 H), 1.58-1.48 (m, 5 H), 1.24-1.02 (m, 4 H), 0.91 (t, 3 H, *J* = 7.2 Hz); MS (FAB) *m/z* 536 (M+H).

4.1.4.4. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-*N*-((2-(isopentylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (10)

81% yield, white solid, mp = 123-126 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.50-7.41 (m, 2 H), 7.28 (s, 1 H), 7.12 (dd, 1 H, *J* = 8.1 Hz), 7.07 (d, 1 H, *J* = 8.1 Hz), 6.98 (bs 1 H), 6.33 (bt, 1 H), 4.36 (m, 2 H), 3.56 (q, 1 H, *J* = 6.9 Hz), 3.22 (t, 2 H, *J* = 7.5 Hz), 3.01 (s, 3 H), 1.93-1.83 (m, 1 H), 1.66 (m, 2 H), 1.18 (d, 3 H, *J* = 7.2 Hz), 0.96 (d, 6 H, *J* = 7.1 Hz); MS (FAB) *m/z* 522 (M+H).

4.1.4.5. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-*N*-((2-(2,2,2-trifluoroethylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (11)

75% yield, white solid, mp = 164-166 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.55-7.42 (m, 2 H), 7.32 (s, 1 H), 7.16 (dd, 1 H, *J* = 8.0 Hz), 7.07 (d, 1 H, *J* = 8.1 Hz), 6.96 (bs 1 H), 6.32 (bt, 1 H), 4.36 (m, 2 H), 3.59 (q, 1 H, *J* = 6.9 Hz), 3.45 (s, 2 H), 3.00 (s, 3 H); MS (FAB) *m/z* 534 (M+H).

4.1.4.6. *N*-((2-(3-Bromopropylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-

(methylsulfonamido)phenyl)propanamide (12)

40% yield, white solid, mp = 100-103 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.48-7.56 (m, 2 H), 7.32 (d, 1 H, *J* = 7.8 Hz), 7.15-7.07 (m, 2 H), 6.62 (bs, 1 H), 6.03 (bt, 1 H), 4.38 (d, 2 H, *J* = 5.7 Hz), 3.60-3.49 (m, 3 H), 3.37 (t, 2 H, *J* = 6.9 Hz), 3.03 (s, 3 H), 2.26 (m, 2 H), 1.50 (d, 3 H, *J* = 6.9 Hz); MS (FAB) *m/z* 573 (M+H).

4.1.4.7. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(3-hydroxypropylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (13)

65% yield, white solid, mp = 93-95 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.57 (dd, 1 H, *J* = 7.8 and 7.8 Hz), 7.49 (d, 1 H, *J* = 7.8 Hz), 7.33 (d, 1 H, *J* = 7.8 Hz), 7.06-7.12 (m, 2 H), 6.61 (bs, 1 H), 5.97 (bt, 1 H), 4.39 (d, 2 H, *J* = 5.7 Hz), 3.70 (m, 2 H), 3.54 (q, 1 H, *J* = 6.9 Hz), 3.36 (m, 2 H), 3.03 (s, 3 H), 1.96 (m, 2 H), 1.50 (d, 3 H, *J* = 6.9 Hz); MS (FAB) *m/z* 510 (M+H).

4.1.4.8. N-((2-(3-(Dimethylamino)propylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (14)

33% yield, white solid, mp = 130-133 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.58-7.49 (m, 2 H), 7.33 (d, 1 H, *J* = 6 Hz), 7.15-7.08 (m, 2H), 5.99 (m, 1 H), 4.40-4.37 (m, 2 H), 3.56 (q, 1 H, *J* = 6 Hz), 3.21-3.17 (m, 2 H), 3.03 (s, 3 H), 2.90-2.84 (m, 2 H), 2.57 (s, 6 H), 2.22-2.14 (m, 2 H), 1.50 (d, 3 H, *J* = 6.0 Hz); MS (FAB) *m/z* 537 (M+H).

4.1.4.9. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(3-(pyrrolidin-1-yl)propylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (15)

78% yield, white solid, mp = 139-141 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.49-7.35 (m, 3 H), 7.23-7.12 (m, 2 H), 4.39-4.25 (m, 2 H), 3.74 (q, 1 H, *J* = 6.0 Hz), 3.30 (m, 1 H), 3.21 (t, 1 H, *J* = 6.0 Hz), 3.10-3.03 (m, 1 H), 2.98 (s, 3 H), 2.89-2.84 (m, 1 H), 2.80 (s, 3 H), 2.25-2.14 (m, 1 H), 2.09-2.00 (m, 1 H), 1.94-1.85 (m, 1 H), 1.46 (d, 3 H, *J* = 6.0 Hz); MS (FAB) *m/z* 563 (M+H).

4.1.4.10. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(3-(piperidin-1-yl)propylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (16)

76% yield, white solid, mp = 137-139 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.57 (d, 1 H, *J* = 7.7 Hz), 7.45 (t, 1 H, *J* = 8.0 Hz), 7.28-7.26 (m, 2 H), 7.07 (d, 1 H, *J* = 9.18 Hz), 6.87 (br s, 1 H), 4.43-4.25 (m, 2 H), 3.69 (q, 1 H), 3.15 (t, 2 H, *J* = 7.14 Hz), 2.99 (s, 3 H), 2.83-2.77 (m, 4 H), 2.05-1.95 (m, 2 H), 1.85 (t, 3 H, *J* = 5.31 Hz), 1.57 (br s, 1 H), 1.48 (d, 2 H, *J* = 7.14 Hz), 1.26 (s, 3 H), 0.87 (m, 1 H); MS (FAB) *m/z* 577 (M+H).

4.1.4.11. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(3-(4-methylpiperidin-1-yl)propylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (17)

82% yield, white solid, mp = 75-78 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.64-7.45 (m, 2 H), 7.32 (d, 1 H, *J* = 9.0 Hz), 7.16-7.09 (m, 2 H), 4.44-4.34 (m, 2 H), 3.56 (q, 1 H, *J* = 9.0 Hz), 3.25-3.17 (m, 2 H), 3.05-2.84 (m, 9 H), 2.17-2.07 (m, 2 H), 0.97 (d, 3 H, *J* = 6.0 Hz); MS (FAB) *m/z* 591 (M+H).

4.1.4.12. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(3-morpholinopropylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (18)

81% yield, white solid, mp = 80-85 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.59-7.48 (m, 2 H), 7.30 (d, 1 H, *J* = 7.68 Hz), 7.07-7.00 (m, 2 H), 5.97 (t, 1 H), 4.44-4.28 (m, 2 H), 3.75 (t, 6 H, *J* = 4.38 Hz), 3.55 (q, 1 H), 3.27-3.13 (m, 2H), 3.01 (s, 3 H), 2.47-2.42 (m, 6 H), 1.82-1.74 (m, 2 H), 1.51-1.48 (d, 4 H, *J* = 6.96 Hz); MS (FAB) *m/z* 579 (M+H).

4.1.4.13. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(2-phenoxyethylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (19)

69% yield, white solid, mp = 88-90 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.58-7.45 (m, 2 H), 7.38-

7.26 (m, 4 H), 7.14-7.04 (m, 2 H), 6.98-6.92 (m, 3 H), 6.10-6.08 (m, 1 H), 4.46-4.30 (m, 1 H), 4.26 (t, 2 H, $J = 6.39$ Hz), 3.63 (t, 2 H, $J = 6.39$ Hz), 3.53 (q, 1 H, $J = 6.0$ Hz), 3.00 (s, 3 H), 1.48 (d, 3 H, $J = 6.0$ Hz); MS (FAB) m/z 572 (M+H).

4.1.4.14. 3-(3-((2-(3-Fluoro-4-(methylsulfonamido)phenyl)propanamido)methyl)-6-(trifluoromethyl)pyridin-2-ylthio)propanoic acid (20)

60% yield, yellow solid, mp = 135-137 °C, ^1H NMR (300 MHz, CDCl_3) δ 11.9 (s, 1 H), 7.56-7.55 (m, 3 H), 7.30 (d, 1 H, $J = 7.8$ Hz), 7.34 (s, 1 H), 7.13-7.09 (m, 2 H), 6.72 (bs, 1 H), 6.11 (bt, 1 H), 4.32 (m, 2 H), 3.53 (q, 1 H, $J = 6.9$ Hz), 3.46 (t, 2 H, $J = 6.6$ Hz), 3.02 (s, 3 H), 2.81 (t, 2 H, $J = 6.7$ Hz), 1.53 (d, 3 H, $J = 6.9$ Hz); MS (FAB) m/z 524 (M+H).

4.1.4.15. Methyl 3-(3-((2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamido)methyl)-6-(trifluoromethyl)pyridin-2-ylthio)propanoate (21)

68% yield, white solid, mp = 117-120 °C, ^1H NMR (300 MHz, CDCl_3) δ 7.57-7.46 (m, 3 H), 7.31 (d, 1 H, $J = 7.8$ Hz), 7.34 (s, 1 H), 7.14-7.01 (m, 2 H), 6.74 (bs, 1 H), 6.15 (bt, 1 H), 4.35 (m, 2 H), 3.70 (s, 3 H), 3.55 (q, 1 H, $J = 6.9$ Hz), 3.47 (t, 2 H, $J = 6.6$ Hz), 3.02 (s, 3 H), 2.78 (t, 2 H, $J = 6.6$ Hz), 1.50 (d, 3 H, $J = 6.9$ Hz); MS (FAB) m/z 538 (M+H).

4.1.4.16. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(3-oxo-3-(pyrrolidin-1-yl)propylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (22)

42% yield, pale yellow solid, mp = 94-96 °C, ^1H NMR (300 MHz, CDCl_3) δ 7.56-7.55 (m, 3 H), 7.30 (d, 1 H, $J = 7.8$ Hz), 7.34 (s, 1 H), 7.13-7.09 (m, 2 H), 6.72 (bs, 1 H), 6.11 (bt, 1 H), 4.32 (m, 2 H), 3.53 (q, 1 H, $J = 6.9$ Hz), 3.49 (t, 4 H, $J = 7.9$ Hz), 3.36 (t, 2 H, $J = 6.7$ Hz), 3.04 (s, 3 H), 2.80 (t, 2 H, $J = 6.7$ Hz), 1.87-1.82 (m, 4 H), 1.54 (d, 3 H, $J = 6.9$ Hz); MS (FAB) m/z 573 (M+H).

4.1.4.17. *N*-((2-(Cyclopentylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (23)

59% yield, yellow solid, mp = 126-129 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.50 (t, 2 H, *J* = 9.0 Hz), 7.27 (d, 1 H, *J* = 9.0 Hz), 7.14-7.06 (m, 2 H), 6.59 (s, 1 H), 6.03 (m, 1 H), 4.42-4.29 (m, 2 H), 4.16-4.07 (m, 1 H), 3.55 (q, 1 H, *J* = 9.0 Hz), 3.02 (s, 2 H), 2.27-2.17 (m, 4 H), 1.75-1.48 (m, 7 H); MS (FAB) *m/z* 520 (M+H).

4.1.4.18. *N*-((2-(Cyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (24)

65% yield, white solid, mp = 70-73 °C, ¹H NMR (300 MHz, CD₃OD) δ 7.48-7.35 (m, 3 H), 7.26 (d, 1 H, *J* = 7.8 Hz), 7.16 (dd, 1 H, *J* = 1.8 and 11.1 Hz), 7.10 (d, 1 H, *J* = 8.4 Hz), 6.13 (bs, 1 H), 4.35 (d, 2 H, *J* = 5.7 Hz), 3.82 (m, 1 H), 3.56 (q, 1 H, *J* = 7.2 Hz), 3.02 (s, 3 H), 2.06 (m, 2 H), 1.75 (m, 2 H), 1.49 (d, 3 H, *J* = 7.2 Hz), 1.33-1.26 (m, 6 H); MS (FAB) *m/z* 534 (M+H).

4.1.4.19. (*S*)-*N*-((2-(Cyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (24S).

[α]_D²⁵ = +18.2 (c 0.1, MeOH), 99% ee, The spectra are identical to those of compound **24**.

4.1.4.20. (*R*)-*N*-((2-(Cyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (24R).

[α]_D²⁵ = -18.5 (c 0.1, MeOH), 98.5% ee, The spectra are identical to those of compound **24**.

4.1.4.21. *N*-((2-(Cyclohexylsulfinyl)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (25)

78% yield, white solid, mp = 68-70 °C, ¹H NMR (300 MHz, DMSO) δ 9.51 (s, 1 H), 8.61 (d, 1

H), 8.05 (d, 1 H), 8.00 (m, 1 H), 7.31 (m, 1 H), 7.22 (m, 1 H), 7.15 (m, 1 H), 4.74 (d, 2 H), 3.78 (m, 2 H), 3.02 (s, 3 H), 1.93 (brs, 2 H), 1.81 (d, 2 H), 1.65 (m, 2 H), 1.47 (m, 2 H), 1.31-1.21 (m, 5 H); MS (FAB) m/z 520 (M+H).

4.1.4.22. *N*-((2-(Cyclohexylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (26)

67% yield, white solid, mp = 68-71 °C, ^1H NMR (300 MHz, DMSO) δ 9.52 (s, 1 H), 8.63 (d, 1 H), 8.15 (d, 1 H), 8.00 (m, 1 H), 7.34 (m, 1 H), 7.24 (m, 1 H), 7.15 (m, 1 H), 4.63 (d, 2 H), 3.71 (m, 2 H), 3.01 (s, 3 H), 1.81-1.69 (m, 4 H), 1.59-1.50 (m, 4 H), 1.37 (d, 3 H), 1.25-1.15 (m, 4 H); MS (FAB) m/z 566 (M+H)

4.1.4.23. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-*N*-((2-(4-methylcyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (27)

66% yield, white solid, mp = 70-75 °C, ^1H NMR (300 MHz, DMSO) δ 9.52 (s, 1 H), 8.59 (d, 1 H), 7.51 (d, 1 H), 7.35 (m, 1 H), 7.25 (m, 1 H), 7.15 (m, 1 H), 4.25 (d, 2 H), 4.00 (m, 2 H), 3.75 (m, 2 H), 3.01 (s, 3 H), 1.85 (s, 2 H), 1.60-1.48 (m, 4 H), 1.28-1.18 (m, 3 H), 0.91 (d, 3 H); MS (FAB) m/z 548 (M+H).

4.1.4.24. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-*N*-((2-(2-methylcyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (28)

65% yield, white solid, mp = 75-78 °C, ^1H NMR (300 MHz, DMSO) δ 9.52 (s, 1 H), 8.59 (d, 1 H), 7.51 (d, 1 H), 7.35 (m, 1 H), 7.25 (m, 1 H), 7.15 (m, 1 H), 4.31 (d, 2 H), 4.25 (m, 2 H), 3.75 (m, 2 H), 3.01 (s, 3 H), 1.80 (s, 2 H), 1.60-1.48 (m, 4 H), 1.40-1.37 (m, 3 H), 0.91 (d, 3 H); MS (FAB) m/z 548 (M+H).

4.1.4.25. *N*-((2-(4-Ethylcyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-

4-(methylsulfonamido)phenyl)propanamide (29)

77% yield, white solid, mp = 73-76 °C, ¹H NMR (300 MHz, DMSO) δ 9.52 (s, 1 H), 8.52 (t, 1 H), 7.51 (d, 1 H), 7.35 (t, 1 H), 7.25 (d, 1 H), 7.15 (d, 1 H), 4.18 (d, 2 H), 3.75 (m, 2 H), 3.01 (s, 3 H), 2.04 (m, 2 H), 1.75 (m, 3 H), 1.25-1.00 (m, 4 H), 0.91 (d, 5 H); MS (FAB) *m/z* 562 (M+H).

4.1.4.26. *N*-((2-(4-*tert*-Butylcyclohexylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (30)

74% yield, white solid, mp = 86-90 °C, ¹H NMR (300 MHz, DMSO) δ 9.52 (s, 1 H), 8.52 (t, 1 H), 7.51 (d, 1 H), 7.35 (t, 1 H), 7.25 (d, 1 H), 7.15 (d, 1 H), 4.17 (d, 2 H), 3.75 (m, 2 H), 3.01 (s, 3 H), 2.14 (m, 2 H), 1.78 (m, 3 H), 1.41 (s, 2 H), 1.25-1.00 (m, 4 H), 0.75 (d, 9 H); MS (FAB) *m/z* 590 (M+H).

4.1.4.27. *N*-((2-(Cyclohexylmethylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (31)

75% yield, white solid, mp = 130-132 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.54-7.49 (m, 2 H), 7.28 (d, 1 H, *J* = 7.8 Hz), 7.15-7.07 (m, 2 H), 6.50 (bs, 1 H), 6.00 (bt, 1 H), 4.40 (m, 2 H), 3.55 (q, 1 H, *J* = 6.9 Hz), 3.14 (d, 2 H, *J* = 6.6 Hz), 3.03 (s, 3 H), 1.85 (m, 2 H), 1.70-1.53 (m, 4 H), 1.49 (d, 3 H, *J* = 6.9 Hz), 0.95-1.28 (m, 5 H); MS (FAB) *m/z* 548 (M+H).

4.1.4.28. *N*-((2-(4-Chlorobenzylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (32)

72% yield, white solid, mp = 96-98 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.55-7.48 (m, 2 H), 7.36-7.31 (m, 3 H), 7.24-7.23 (m, 1 H), 7.13-7.04 (m, 2 H), 6.47 (s, 1 H), 5.88 (m, 1 H), 4.42 (s, 2 H), 4.34 (t, 2 H, *J* = 6.0 Hz), 3.49 (q, 1 H, *J* = 7.2 Hz), 3.02 (s, 3 H), 1.47 (d, 3 H, *J* = 7.2 Hz); MS (FAB) *m/z* 576 (M+H).

4.1.4.29. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(4-methylbenzylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (33)

81% yield, white solid, mp = 145-147 °C, ¹H NMR (300 MHz, CD₃OD) δ 7.47-7.36 (m, 3 H), 7.28-7.26 (m, 2 H), 7.22-7.12 (m, 2 H), 7.04 (d, 2 H, *J* = 7.68 Hz), 4.41 (s, 2 H), 4.28 (d, 2 H, *J* = 5.31 Hz), 3.71 (q, 1 H), 2.97 (s, 3 H), 2.27 (s, 3 H), 1.44 (d, 3 H, *J* = 6.96 Hz); MS (FAB) *m/z* 556 (M+H).

4.1.4.30. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(4-methoxybenzylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (34)

84% yield, white solid, mp = 158-161 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.55-7.45 (m, 2 H), 7.34-7.30 (m, 3 H), 7.17-7.03 (m, 2 H), 6.84-6.80 (m, 2 H), 6.60 (s, 1 H), 5.97 (m, 1 H), 4.42 (s, 2 H), 4.38-4.27 (m, 2 H), 3.78 (s, 3 H), 3.50 (q, 1 H, *J* = 6.0 Hz), 3.01 (s, 3 H), 1.46 (d, 3 H, *J* = 6.0 Hz); MS (FAB) *m/z* 572 (M+H).

4.1.4.31. N-((2-(2-Chlorobenzylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(3-fluoro-4-(methylsulfonamido)phenyl)propanamide (35)

85% yield, white solid, mp = 161-163 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.61-7.55 (m, 2 H), 7.51-7.46 (m, 1 H), 7.39-7.32 (m, 2 H), 7.23-7.14 (m, 1 H), 7.12-7.07 (m, 1 H), 7.05-7.03 (m, 1 H), 6.45 (s, 1 H), 5.95 (m, 1 H), 4.60 (s, 2 H), 4.32 (m, 2 H), 3.49 (q, 1 H, *J* = 7.5 Hz), 3.02 (s, 3 H), 1.45 (d, 3 H, *J* = 7.5 Hz); MS (FAB) *m/z* 576 (M+H).

4.1.4.32. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((6-(trifluoromethyl)-2-(3-(trifluoromethyl)benzylthio)pyridin-3-yl)methyl)propanamide (36)

70% yield, white solid, mp = 165-167 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.72 (s, 1 H), 7.63-7.48 (m, 4 H), 7.43-7.32 (m, 2 H), 7.14-7.05 (m, 2 H), 6.45 (s, 1 H), 5.89 (m, 1 H), 4.49 (s, 2 H), 4.34 (m, 2 H), 3.52 (q, 1 H, *J* = 6.0 Hz), 3.02 (s, 3 H), 1.48 (d, 3 H, *J* = 9.0 Hz); MS (FAB) *m/z* 610

(M+H).

4.1.4.33. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(furan-2-ylmethylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (37)

72% yield, white solid, mp = 143-145 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.59-7.48 (m, 2 H), 7.35-7.33 (m, 2 H), 7.13-7.04 (m, 2 H), 6.49 (s, 1 H), 6.29-6.28 (m, 2 H), 5.95-5.93 (m, 1 H), 4.53 (s, 2 H), 4.35 (Septet, 2 H), 3.52 (q, 1 H), 3.03 (s, 2 H), 1.58 (s, 2 H), 1.48 (d, 3 H), 1.25 (m, 4 H), 0.95-0.8 (m, 3 H); MS (FAB) *m/z* 532 (M+H).

4.1.4.34. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(thiophen-2-ylmethylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (38)

84% yield, white solid, mp = 126-129 °C, ¹H NMR (300 MHz, CDCl₃) δ 7.57 (d, 1 H, *J* = 6.0 Hz), 7.47 (t, 1 H, *J* = 6.0 Hz), 7.34 (d, 1 H, *J* = 6.0 Hz), 7.17-7.03 (m, 4 H), 6.90-6.87 (m, 1 H), 6.61 (s, 1 H), 6.02 (t, 1 H, *J* = 6.0 Hz), 4.71 (s, 2 H), 4.41-4.27 (septet, 2 H), 3.51 (q, 1 H, *J* = 6.0 Hz), 3.0 (s, 3 H), 1.46 (d, 3 H, *J* = 6.0 Hz); MS (FAB) *m/z* 548 (M+H).

4.1.4.35. 2-(3-Fluoro-4-(methylsulfonamido)phenyl)-N-((2-(phenethylthio)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide (39)

68% yield, white solid, mp = 135-139 °C, ¹H NMR (300 MHz, CD₃OD) δ 7.44 (d, 2 H, *J* = 8.25 Hz), 7.35-7.15 (m, 10 H), 4.33 (d, 2 H, *J* = 3.12 Hz), 3.71 (q, 1 H), 3.43 (t, 2 H), 3.34 (t, 2 H), 2.98 (s, 3 H), 1.49 (d, 3 H, *J* = 7.14 Hz); MS (FAB) *m/z* 556 (M+H).

4.2. Molecular modeling

The 3D structure of the ligand was generated with Concord and energy minimized using MMFF94s force field and MMFF94 charge until the rms of Powell gradient was 0.05 kcal mol⁻¹ Å⁻¹ in SYBYL-X 1.2 (Tripos Int., St. Louis, MO, USA). The flexible docking study on our

hTRPV1 model^{17,23} was performed by GOLD v.5.0.1 (Cambridge Crystallographic Data Centre, Cambridge, UK), which uses a genetic algorithm (GA) and allows for full ligand flexibility and partial protein flexibility. The binding site was defined as 8 Å around the capsaicin docked in the hTRPV1 model. The side chains of the nine residues, which are important for ligand binding, (i.e., Tyr511, Ser512, Met514, Leu515, Leu518, Phe543, Leu547, Thr550, and Asn551) were set to be flexible with 'crystal mode' in GOLD. The ligand was docked using the GoldScore scoring function with 30 GA runs. Other parameters were set as default. All computation calculations were undertaken on Intel® Xeon™ Quad-core 2.5 GHz workstation with Linux Cent OS release 5.5.

4.3. Biological Assay

The methods for *in vitro* and *in vivo* assays were reported in the previous literature.¹⁷

Acknowledgements

This research was supported by Research Grants from Grunenthal, Grants from the National Research Foundation of Korea (NRF) (R11-2007-107-02001-0), Grants from the National Leading Research Lab (NLRL) program (2011-0028885), and in part by the Intramural Research Program of NIH, Center for Cancer Research, NCI (Project Z1A BC 005270).

References and Notes

1. Szallasi, A.; Blumberg, P. M. *Pharmacol. Rev.* **1999**, 51, 159.
2. Tominaga, M.; Caterina, M. J.; Malmberg, A. B.; Rosen, T. A.; Gilbert, H.; Skinner, K.; Raumann, B. E.; Basbaum, A. I.; Julius, D. *Neuron* **1998**, 21, 531.
3. Caterina, M. J.; Schumacher, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. *Nature* **1997**, 389, 816.
4. Zygmunt, P. M.; Petersson, J.; Andersson, D. A.; Chuang, H-H.; Sorgard, M.; Di Marzo, V.;

- Julius, D.; Hogestatt, E. D. *Nature* **1999**, 400, 452.
5. Hwang, S. W.; Cho, H.; Kwak, J.; Lee, S. Y.; Kang, C. J.; Jung, J.; Cho, S.; Min, K. H.; Suh, Y. G.; Kim, D.; Oh, U. *Proc. Natl. Acad. Sci. USA* **2000**, 97, 6155.
6. Walpole, C. S. J.; Wrigglesworth, R. *Capsaicin in the Study of Pain*; Academic Press: San Diego, CA, 1993; pp 63.
7. Appendino, G.; Szallasi, A. *Life Sci.* **1997**, 60, 681.
8. Szallasi, A.; Cruz, F.; Geppetti, P. *Trends in Mol. Med.* **2006**, 12, 545.
9. Kym, P. R.; Kort, M. E.; Hutchins, C. W. *Biochem. Pharmacol.* **2009**, 78, 211.
10. Wong, G. Y.; Gavva, N. R. *Brain Res. Rev.* **2009**, 60, 267.
11. Gunthorpe, M. J.; Chizh, B. A. *Drug Disc. Today* **2009**, 14, 56.
12. Lazar, J.; Gharat, L.; Khairathkar-Joshi, N.; Blumberg, P. M.; Szallasi, A. *Exp. Opin. Drug Discov.* **2009**, 4, 159.
13. Voight, E. A.; Kort, M. E. *Exp. Opin. Ther. Pat.* **2010**, 20, 1.
14. Szolcsányi, J.; Sándor, Z. *Trend Pharmacol. Sci.* **2012**, 33, 646.
15. Szallasi, A.; Sheta, M. *Exp. Opin. Investig. Drug* **2012**, 21, 1351.
16. Kim, Y. S.; Kil, M-J.; Kang, S-U.; Ryu, H.; Kim, M. S.; Cho, Y.; Bhondwe, R. S.; Thorat, S. A.; Sun, W.; Liu, K.; Lee, J. H.; Choi, S.; Pearce, L. V.; Pavlyukovets, V. A.; Morgan, M. A.; Tran, R.; Lazar, J.; Blumberg, P. M.; Lee, J. *Bioorg. Med. Chem.* **2012**, 20, 215.
17. Kim, M. S.; Ryu, H.; Kang, D. W.; Cho, S-H.; Seo, S.; Park, Y. S.; Kim, M-Y.; Kwak, E. J.; Kim, Y. S.; Bhondwe, R. S.; Kim, H. S.; Park, S-g. Son, K.; Choi, S.; DeAndrea-Lazarus, I.; Pearce, L. V.; Blumberg, P. M.; Frank, R.; Bahrenberg, G.; Stockhausen, H.; Kögel, B. Y.; Schiene, K.; Christoph, T.; Lee, J. *J. Med. Chem.* **2012**, 55, 8392.
18. Thorat, S. A.; Kang, D. W.; Ryu, H.; Kim, M. S.; Kim, H. S.; Ann, J.; Ha, T-H.; Kim, S. E.; Son, K.; Choi, S.; Blumberg, P. M.; Frank, R.; Bahrenberg, G.; Schiene, K.; Christoph, T.; Lee, J. *Euro. J. Med. Chem.* **2013**, 64, 589.

19. Ryu, H.; Jin, M-K.; Kang, S-U.; Kim, S. Y.; Kang, D. W.; Lee, J.; Pearce, L. V.; Pavlyukovets, V. A.; Morgan, M. A.; Tran, R.; Toth, A.; Lundberg, D. J.; Blumberg, P. M. *J. Med. Chem.* **2008**, 51, 57.
20. Bennett, G. J.; Xie, Y-K. *Pain* **1988**, 33, 87.
21. Szikszay, M.; Obál F. Jr.; Obál, F. *Naunyn Schmiedebergs Arch Pharmacol.* **1982**, 320, 97.
22. De Vries, D. J., Blumberg, P. M. *Life Sci.* **1989**, 44, 711.
23. Lee, J. H.; Lee, Y.; Ryu, H.; Kang, D. W.; Lee, J.; Lazar, J.; Pearce, L. V.; Pavlyukovets, V. A.; Blumberg, P. M.; Choi, S. *J. Comput. Aided Mol. Des.* **2011**, 25, 317.

TRPV1 Antagonist with High Analgesic Efficacy: 2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides

Tae-Hwan Ha, HyungChul Ryu, Sung-Eun Kim, Ho Shin Kim, Jihyae Ann, Phuong-Thao Tran, Van-Hai Hoang, Karam Son, Minghua Cui, Sun Choi, Peter M. Blumberg, Robert Frank, Gregor Bahrenberg, Klaus Schiene, Thomas Christoph, Sven Frommann, Jeewoo Lee *

